All In Biotech

Drug Trial Radar · NCT04249323

Single and Multiple Ascending Dose Study of CORT113176 in Healthy Participants

A Phase 1 Adaptive Dose, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally Administered CORT113176 in Healthy Subjects, With an Optional Pharmacological Effects Cohort

Last checked: Nov 19, 2026Latest source record: Feb 1, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 110 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

110

Actual

Start

Jan 27, 2020

Primary completion

Oct 15, 2020

Study completion Oct 15, 2020

Sponsor

Lead sponsor
Corcept TherapeuticsIndustry
Sponsor type
Industry
First posted
Jan 30, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a 3-part, first-in-human study of single ascending doses (SAD; Part 1) and multiple ascending doses (MAD; Part 2) of CORT113176 in healthy participants; Part 3 is an optional part to investigate whether CORT113176 ameliorates the effects of prednisone on various pharmacodynamic (PD) endpoints. The 3 parts may not be conducted entirely sequentially provided that this is justified by pharmacokinetic (PK) and safety data obtained from completed cohorts. The first MAD cohort will not start until data are available from at least 2 SAD levels to allow MAD administration in the fasted state, or until after a food-effect cohort has been dosed in the SAD phase to allow MAD administration in the fed state. The expected exposure for the daily MAD level at steady state (taking into consideration potential accumulation on repeat dosing) must not exceed the highest exposure considered to be safe and well tolerated during preceding SAD cohorts.

Conditions

  • Healthy Adults

Interventions

  • CORT113176 Lipid Capsule FormulationDrug

    CORT113176 Lipid Capsule Formulation 10-200 mg for oral administration

  • Placebo matching CORT113176 Lipid Capsule FormulationDrug

    Placebo matching CORT113176 Lipid Capsule Formulation 10-200 mg for oral administration

  • PrednisoneDrug

    Prednisone standard release tablets 1 x 20 mg plus 1 x 5 mg for oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with One or More Adverse EventsTime frame: Part 1 SAD Cohorts: up to Day 9; Part 2 MAD Cohorts: up to Day 23; Part 3 Cohort: up to Day 19

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Quotient Sciences

    Ruddington, Nottingham, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.